Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135963 | 0.87 | LMNA (0.48) | LMNAALDH1A1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL4127772 | 0.83 | KMT2A (0.42) | LMNAALDH1A1BDKRB1HSD11B1POLB | |
| SCHEMBL4139487 | 0.78 | LMNA (0.38) | LMNAALDH1A1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL4139482 | 0.78 | LMNA (0.38) | LMNAALDH1A1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL4145495 | 0.72 | F13A1 (0.44) | LMNAALDH1A1HTT | |
| SCHEMBL4127774 | 0.70 | KMT2A (0.45) | LMNAALDH1A1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL5437654 | 0.68 | HTT (0.57) | LMNAALDH1A1HTTBDKRB1NR1H3 | |
| SCHEMBL4134996 | 0.68 | GAA (0.40) | SMN1; SMN2BDKRB1GAAGSTO1 | |
| SCHEMBL3957305 | 0.68 | HTT (0.60) | LMNAALDH1A1HTTBDKRB1NR1H3 | |
| SCHEMBL4029806 | 0.68 | ALDH1A1 (0.64) | LMNAALDH1A1HTTSMN1; SMN2BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | LMNA 3671/4885ALDH1A1 1565/4885HTT 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.